You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Cancer, Multiple Myeloma (MM), Relapsed or Refractory Multiple Myeloma (R/R MM), pharmacokinetics

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma Trial in Shenyang (IM21 CAR-T cells)

Recruiting
  • Multiple Myeloma
  • IM21 CAR-T cells
  • Shenyang, Liaoning, China
    Hospital of China Medical University
Jul 26, 2022

Multiple Myeloma Trial (Elranatamab, Elotuzumab, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Nov 28, 2023

Learn About Medicine in People With Relapsed Refractory Multiple

Completed
  • Multiple Myeloma
  • New York, New York
    Pfizer
Nov 14, 2022

Multiple Myeloma Trial in Charlotte (Elotuzumab)

Active, not recruiting
Has Results
  • Multiple Myeloma
  • Charlotte, North Carolina
    Levine Cancer Institute
Jan 24, 2023

Multiple Myeloma Trial in Xuzhou (anti-BCMA/GPRC5D CAR-T CELL)

Recruiting
  • Multiple Myeloma
  • anti-BCMA/GPRC5D CAR-T CELL
  • Xuzhou, Jiangsu, China
    Kailin Xu
Aug 19, 2022

Multiple Myeloma Trial in Tianjin (Anlotinib Hydrochloride Capsule)

Recruiting
  • Multiple Myeloma
  • Anlotinib Hydrochloride Capsule
  • Tianjin, Tianjin, China
    InstituteHBDH
Sep 18, 2022

Relapsed and Refractory Multiple Myeloma Trial in Pittsburgh (Mezigdomide, Ixazomib, Dexamethasone)

Not yet recruiting
  • Relapsed and Refractory Multiple Myeloma
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 15, 2023

Relapsed Refractory Multiple Myeloma Trial (REGN5458, Elotuzumab, Pomalidomide)

Not yet recruiting
  • Relapsed Refractory Multiple Myeloma
  • (no location specified)
Feb 6, 2023

Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma Trial in Boston (Isatuximab, Belantamab mafodotin, Pomalidomide)

Not yet recruiting
  • Relapsed Cancer
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jun 19, 2023

Multiple Myeloma Trial in Houston (Belumosudil mesylate)

Not yet recruiting
  • Multiple Myeloma
  • Belumosudil mesylate
  • Houston, Texas
    M D Anderson Cancer Center
Oct 31, 2023

Multiple Myeloma Trial in Adelaide, Melbourne, Oslo (XmAb24306, Daratumumab)

Recruiting
  • Multiple Myeloma
  • Adelaide, South Australia, Australia
  • +2 more
Aug 1, 2022

Selinexor in Relapsed or Refractory Multiple Myeloma - SEATTLE-

Recruiting
  • Multiple Myeloma
  • Wien, Austria
  • +1 more
Jul 13, 2023

Biomarker for Infection Risk in CLL and MM

Not yet recruiting
  • Multiple Myeloma
  • Chronic Lymphocytic Leukemia
  • Screening
  • Boston, Massachusetts
    Massachusetts General Hospital Cancer Center
May 3, 2023

Multiple Myeloma, Multiple Myeloma in Relapse Trial in Boston (Ixazomib, Pomalidomide, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Multiple Myeloma in Relapse
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Apr 13, 2022

Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis (Nicotinamide Expanded Haploidentical

Completed
  • Multiple Myeloma
  • +7 more
  • Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Nov 2, 2022

Relapsed or Refractory Multiple Myeloma Trial in Tianjin (QLS32015)

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jun 24, 2023

Multiple Myeloma Trial in Torino (Carfilzomib, Pomalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Torino, Italy
    Dipartimento di Biotecnologie Molecolari e Scienze per la Salute
Mar 24, 2022

Patients With Relapsed/Refractory Multiple Myeloma

Not yet recruiting
  • Relapsed and Refractory Multiple Myeloma (RRMM)
  • Non-Interventional
  • (no location specified)
Dec 21, 2022

Multiple Myeloma Trial in Salt Lake City (Budesonide EC, Placebo)

Not yet recruiting
  • Multiple Myeloma
  • Budesonide EC
  • Placebo
  • Salt Lake City, Utah
    Huntsman Cancer Institute at the University of Utah
Jan 9, 2023

Multiple Myeloma Trial in Worldwide (Cevostamab, Tocilizumab, Pomalidomide)

Recruiting
  • Multiple Myeloma
  • Duarte, California
  • +7 more
Aug 17, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta (Tocilizumab, Venetoclax)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Jan 24, 2023

Multiple Myeloma (MM) Trial in Japan (OPC-415)

Recruiting
  • Multiple Myeloma (MM)
  • OPC-415
  • Isehara-shi, Japan
  • +4 more
Apr 20, 2022

Multiple Myeloma Trial in Cleveland (Palliative Care, FACT-MM questionnaire, HADS questionnaire)

Recruiting
  • Multiple Myeloma
  • Palliative Care
  • +2 more
  • Cleveland, Ohio
    Cleveland Clinic, Case Comprehensive Cancer Center
Jan 17, 2023

Multiple Myeloma Trial in United States (IGM-2644)

Recruiting
  • Multiple Myeloma
  • Duarte, California
  • +4 more
Jun 9, 2023

Multiple Myeloma (MM), DLBCL, Not Otherwise Specified, Double Hit Lymphoma Trial in Spain (IDP-121)

Recruiting
  • Multiple Myeloma (MM)
  • +5 more
  • Santander, Cantabria, Spain
  • +4 more
Jun 19, 2023